Update shared on 22 Nov 2025
Analysts have maintained their price target for Arcutis Biotherapeutics at $31.00, citing stable growth estimates and consistent profit margin expectations.
What's in the News
- The FDA accepted a supplemental New Drug Application (sNDA) for ZORYVE cream 0.3% to treat plaque psoriasis in children aged 2 to 5. The target action date is set for June 29, 2026. (Key Developments)
- Arcutis commercially launched ZORYVE cream 0.05% for mild to moderate atopic dermatitis in children ages 2 to 5 in the United States. (Key Developments)
- The American Journal of Clinical Dermatology published long-term safety and efficacy data for ZORYVE foam 0.3% in seborrheic dermatitis, confirming its positive benefit over 52 weeks. (Key Developments)
- New clinical data will be presented at the 2025 Fall Clinical Dermatology Conference showing ZORYVE creams improve sleep and provide long-term disease control in atopic dermatitis patients aged 2 and older. (Key Developments)
- Arcutis Biotherapeutics set full-year 2026 revenue guidance at $455 million to $470 million. (Key Developments)
Valuation Changes
- Consensus Analyst Price Target remains unchanged at $31.00 per share.
- Discount Rate has risen slightly from 6.87% to 7.04%.
- Revenue Growth Estimate is stable at approximately 31.56%.
- Net Profit Margin remains consistent, holding at about 35.91%.
- Future P/E has fallen slightly from 20.38x to 19.60x.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.